Success Metrics

Completion Rate
0%(0/2)
Active Trials
1(20%)
Terminated
2(40%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Terminated(3)
Other(1)

Detailed Status

Terminated2
Recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

recruiting120%
terminated240%
unknown120%
withdrawn120%

Recent Activity

1 active trials
Showing 5 of 5
terminatedphase_1

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

NCT05743036
recruitingphase_1

A Study of ZN-c3 in Patients With Ovarian Cancer

NCT04516447
terminatedphase_1

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

NCT05682170
withdrawnphase_1

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

NCT05431582
unknownphase_1

A Phase 1b Study of ZN-c3 in Chinese Subjects

NCT04972422

Clinical Trials (5)

Showing 5 of 5 trials
NCT05743036Phase 1

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Terminated
NCT04516447Phase 1

A Study of ZN-c3 in Patients With Ovarian Cancer

Recruiting
NCT05682170Phase 1

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Terminated
NCT05431582Phase 1

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Withdrawn
NCT04972422Phase 1

A Phase 1b Study of ZN-c3 in Chinese Subjects

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5